Disruptions in access to treatment and harm reduction services could set back effort to eliminate hep C in the U.S.

A companion study will look at liver biopsy results to confirm these findings from noninvasive tests.

However, some 10% experienced liver decompensation even after antiviral therapy.

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.

Compared with current practices, routine screening could prevent 23,000 deaths from liver disease.

Low-barrier care and access to multiple services in one place can improve outcomes for people experiencing homelessness or unstable housing.

Positive diagnostic tests and drug prescriptions dropped 40% in July 2020 compared with earlier years.

Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.